AstraZeneca PLC
AZN.LHealthcareLSEDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, AstraZeneca PLC (AZN.L) is listed under Drug Manufacturers - General. Valued at $214.05B, AZN.L is a mega-cap name in its sector. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Market Cap
$214.05B
Beta
0.22
P/E (TTM)
28.00
P/E (Fwd)
15.94
EPS (TTM)
$4.94
EPS (Fwd)
$8.64
ROE
23.5%
ROA
8.5%
Cash
$7.67B
Total Debt
$34.03B
Free CF
$6.56B
52W Change
29.9%
Annual Financials
Cash vs Debt
On the balance sheet, AZN.L has $7.67B in cash with $34.03B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $6.56B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 23.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $44.35B (2022) to $58.74B (2025), reflecting a 32% increase over the period.
With a beta below 0.7, AstraZeneca PLC typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing AZN.L's risk profile alongside its fundamentals and technical indicators provides a more complete picture.